Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer

Abstract Cardiotoxic manifestation associated with breast cancer treatment by anthracycline regimen increases patients’ susceptibility to myocardial injury, reduction in left ventricular ejection fraction and complications associated with heart failure. There is currently no standardized, minimally...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hari Vishal Lakhani, Sneha S. Pillai, Mishghan Zehra, Benjamin Dao, Maria Tria Tirona, Ellen Thompson, Komal Sodhi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/43f4b838effc46a2b3b54fd017e269af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43f4b838effc46a2b3b54fd017e269af
record_format	dspace
spelling	oai:doaj.org-article:43f4b838effc46a2b3b54fd017e269af2021-12-02T14:26:20ZDetecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer10.1038/s41598-021-87209-82045-2322https://doaj.org/article/43f4b838effc46a2b3b54fd017e269af2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87209-8https://doaj.org/toc/2045-2322Abstract Cardiotoxic manifestation associated with breast cancer treatment by anthracycline regimen increases patients’ susceptibility to myocardial injury, reduction in left ventricular ejection fraction and complications associated with heart failure. There is currently no standardized, minimally invasive, cost effective and clinically verified procedure to monitor cardiotoxicity post-anthracycline therapy initiation, and to detect early onset of irreversible cardiovascular complications. This study aims to create a panel of novel biomarkers and circulating miRNAs associated with cardiotoxicity, further assessing their correlation with cardiac injury specific markers, troponin I and T, and demonstrate the development of cardiac dysfunction in breast cancer patients. Blood obtained from West Virginian females clinically diagnosed with breast cancer and receiving anthracyclines showed upregulated level of biomarkers and circulating miRNAs after 3 and 6 months of chemotherapy initiation with increased levels of cardiac troponin I and T. These biomarkers and miRNAs significantly correlated with elevated troponins. Following 6 months of anthracycline-regimens, 23% of the patient population showed cardiotoxicity with reduced left ventricular ejection fraction. Our results support the clinical application of plasma biomarkers and circulating miRNAs to develop a panel for early diagnosis of chemotherapy related cardiac dysfunction which will enable early detection of disease progression and management of irreversible cardiac damage.Hari Vishal LakhaniSneha S. PillaiMishghan ZehraBenjamin DaoMaria Tria TironaEllen ThompsonKomal SodhiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hari Vishal Lakhani Sneha S. Pillai Mishghan Zehra Benjamin Dao Maria Tria Tirona Ellen Thompson Komal Sodhi Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer
description	Abstract Cardiotoxic manifestation associated with breast cancer treatment by anthracycline regimen increases patients’ susceptibility to myocardial injury, reduction in left ventricular ejection fraction and complications associated with heart failure. There is currently no standardized, minimally invasive, cost effective and clinically verified procedure to monitor cardiotoxicity post-anthracycline therapy initiation, and to detect early onset of irreversible cardiovascular complications. This study aims to create a panel of novel biomarkers and circulating miRNAs associated with cardiotoxicity, further assessing their correlation with cardiac injury specific markers, troponin I and T, and demonstrate the development of cardiac dysfunction in breast cancer patients. Blood obtained from West Virginian females clinically diagnosed with breast cancer and receiving anthracyclines showed upregulated level of biomarkers and circulating miRNAs after 3 and 6 months of chemotherapy initiation with increased levels of cardiac troponin I and T. These biomarkers and miRNAs significantly correlated with elevated troponins. Following 6 months of anthracycline-regimens, 23% of the patient population showed cardiotoxicity with reduced left ventricular ejection fraction. Our results support the clinical application of plasma biomarkers and circulating miRNAs to develop a panel for early diagnosis of chemotherapy related cardiac dysfunction which will enable early detection of disease progression and management of irreversible cardiac damage.
format	article
author	Hari Vishal Lakhani Sneha S. Pillai Mishghan Zehra Benjamin Dao Maria Tria Tirona Ellen Thompson Komal Sodhi
author_facet	Hari Vishal Lakhani Sneha S. Pillai Mishghan Zehra Benjamin Dao Maria Tria Tirona Ellen Thompson Komal Sodhi
author_sort	Hari Vishal Lakhani
title	Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer
title_short	Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer
title_full	Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer
title_fullStr	Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer
title_full_unstemmed	Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer
title_sort	detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in west-virginian population with breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/43f4b838effc46a2b3b54fd017e269af
work_keys_str_mv	AT harivishallakhani detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT snehaspillai detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT mishghanzehra detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT benjamindao detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT mariatriatirona detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT ellenthompson detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer AT komalsodhi detectingearlyonsetofanthracyclinesinducedcardiotoxicityusinganovelpanelofbiomarkersinwestvirginianpopulationwithbreastcancer
_version_	1718391364026105856

Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer

Ejemplares similares